Addison Capital Co Boosts Stock Position in Johnson & Johnson $JNJ

Addison Capital Co increased its holdings in Johnson & Johnson (NYSE:JNJ) by 5.6% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 45,766 shares of the company’s stock after purchasing an additional 2,443 shares during the period. Johnson & Johnson makes up about 2.0% of Addison Capital Co’s investment portfolio, making the stock its 11th largest position. Addison Capital Co’s holdings in Johnson & Johnson were worth $11,187,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Auto Owners Insurance Co boosted its stake in shares of Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after purchasing an additional 69,108,368 shares during the period. Norges Bank purchased a new stake in Johnson & Johnson in the 4th quarter worth about $6,924,523,000. Capital World Investors bought a new stake in Johnson & Johnson in the fourth quarter worth about $2,005,942,000. Diamant Asset Management Inc. boosted its position in shares of Johnson & Johnson by 24,436.5% during the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock valued at $109,338,000 after buying an additional 4,454,778 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock worth $49,740,362,000 after buying an additional 3,731,074 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ stock opened at $258.48 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The business has a 50-day moving average price of $236.47 and a 200 day moving average price of $232.88. The company has a market capitalization of $622.22 billion, a P/E ratio of 29.88, a PEG ratio of 2.58 and a beta of 0.24. Johnson & Johnson has a 1-year low of $154.80 and a 1-year high of $269.43.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. During the same quarter in the previous year, the business posted $2.77 EPS. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 11.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a dividend of $1.34 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date was Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 61.97%.

Analysts Set New Price Targets

A number of research firms have weighed in on JNJ. Wells Fargo & Company increased their target price on Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 15th. Johnson Rice set a $270.00 target price on shares of Johnson & Johnson in a research note on Friday, June 26th. Citigroup upped their price target on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a report on Wednesday. Leerink Partners raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price objective for the company in a research report on Wednesday, May 13th. Finally, The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $257.74.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, a new ablation catheter platform that could strengthen its electrophysiology business and help drive future growth. Article Title
• Positive Sentiment: Jim Cramer said Johnson & Johnson “will have lots of good news” about its blockbuster drugs, adding to bullish sentiment around the stock. Article Title
• Positive Sentiment: Zacks highlighted JNJ’s strong earnings surprise history and said the company has the ingredients to beat estimates again in its next quarterly report, reinforcing confidence ahead of earnings. Article Title
• Positive Sentiment: TipRanks included Johnson & Johnson among Dividend Aristocrat stocks with a “Strong Buy” rating from top analysts, which may support demand for the shares. Article Title
• Neutral Sentiment: Several broader healthcare and market commentary pieces referenced JNJ as a defensive Dividend Aristocrat, but these were mostly general background items rather than company-specific catalysts. Article Title
• Negative Sentiment: Recent coverage also noted that JNJ had slipped in the prior session, suggesting some near-term profit-taking even as longer-term fundamentals remain intact. Article Title

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.